Novel Approach for Evaluating and Treating Advanced Breast Cancer Patients Whose Tumors Overexpress HER-2/neu
Abstract
The goal of this research is to develop stable radioimmunoconjugates (RICs) of and-HER2/neu antibodies (MoAbs) for imaging and therapy in an animal model bearing human breast tumors. Pharmacy-grade Herceptin and an and-HER2/neu antibody were conjugated with a DTPA linker. (111)nCl3 and (90)YCI3 were labeled to MoAb-CHX-A"-DTPA according to the procedure of Clarke et al. (Cancer Res 60: 4804, 2000). Binding capacity of RICs was tested with human cancer cell lines MCF-7, HCC-1954, BT-474 and SKBR- 3.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2002
- Accession Number
- ADA407296
Entities
People
- Jeffrey Medin
- Micahel J. Blend
- Steven M. Swanson
Organizations
- University of Illinois at Chicago